Fiasp® Demonstrated Effective Overall Blood Sugar Reductions in People With Advanced Type 2 Diabetes Uncontrolled on Multiple Daily Injections (Basal-bolus Regimen)
Bagsværd, Denmark (ots/PRNewswire) - New data presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with advanced type 2 diabetes (>=10 years of diagnosis) not optimally controlled on their current basal-bolus regimen, Fiasp® (fast-acting ...